CD274 and non-small cell lung carcinoma: The first study reported was CANOPY-2, which evaluated canakinumab with docetaxel among 237 patients with locally advanced or metastatic NSCLC who were previously treated with an anti-PD1 or PD-L1 immune checkpoint inhibitor and platinum-based chemotherapy.